Thymosin Alpha-1 Peptide

## What it is Thymosin alpha-1 (Ta1, brand name Zadaxin, generic thymalfasin) is a 28-amino-acid synthetic peptide identical to an N-terminally acetylated peptide first isolated from thymic tissue extracts in the 1970s by Allan Goldstein's group. It is one of the few peptide immunomodulators with a substantial regulated approval footprint: SciClone Pharmaceuticals received approvals in over 35 countries (predominantly in Asia, Europe, and Latin America) for indications including chronic hepatitis B, hepatitis C combination therapy with interferon and ribavirin, immunocompromised vaccine response, and oncology adjunct use. The US is a notable exception. Ta1 advanced through phase 3 trials in chronic hepatitis B and hepatitis C in the United States but did not receive FDA approval; SciClone elected to pursue international markets instead. The compound is therefore not FDA approved but is a regulated prescription drug in much of the world. WADA has not placed Ta1 on the Prohibited List as of 2026. Within US borders, Ta1 is compounded by 503A/503B pharmacies for off-label use under prescription, predominantly through immune-focused functional medicine practices and post-COVID immune-support contexts. The grey-market research-peptide supply also exists but is structurally distinct from the rest of the peptides on this site because Ta1 has a substantial international regulated supply. ## Mechanism of action Ta1 modulates both adaptive and innate immunity through multiple receptor and signaling pathways. The most characterized effect is on T-cell maturation: Ta1 promotes thymocyte differentiation, increases CD4+ and CD8+ T-cell production, and modulates the Th1/Th2 balance toward Th1 polarization in immunocompromised states. Additional effects include stimulation of NK cell activity, modulation of toll-like receptor signaling (particularly TLR2 and TLR9 in dendritic cells), and downregulation of inflammatory cytokines in some contexts. The pharmacologic premise that emerges from this mechanism is context-dependent immune restoration: in immunocompromised states (chronic viral infection, HIV, cancer chemotherapy, vaccine non-response in elderly populations) Ta1 augments T-cell function, while in autoimmune or inflammatory states the modulatory effect can be more nuanced. This bidirectional immune-modulator framing is characteristic of the entire thymic-peptide class. Plasma half-life is approximately 2 hours after subcutaneous injection. Twice-weekly dosing is the standard label schedule across approved indications, reflecting the durable downstream immune effects despite the moderate plasma window. ## Evidence base The Ta1 clinical evidence base is the most substantial of any peptide on this site outside the FDA-approved pharmaceuticals like tirzepatide and semaglutide. Hundreds of trials totaling tens of thousands of participants have been conducted across hepatitis B, hepatitis C, oncology adjunct settings, and vaccine response in elderly cohorts. In chronic hepatitis B, Andreone 2001 and several subsequent meta-analyses reported sustained virologic response rates roughly comparable to standard interferon monotherapy, with Ta1 producing fewer adverse events. Combination with interferon reported synergistic effects in some trials but heterogeneous results across studies. In hepatitis C, Ta1 plus pegylated interferon plus ribavirin produced sustained virologic response improvements over interferon plus ribavirin alone in some populations (Ciancio 2010), though the era of direct-acting antivirals has substantially displaced the clinical role. In oncology, Ta1 has been studied as adjunct therapy in non-small-cell lung cancer, melanoma, and other malignancies. Garaci 2008 and subsequent trials reported modest improvements in immune parameters and disease-free survival in some indications, though no major guideline body has incorporated it into standard care. The most contemporary surge in Ta1 attention came during the COVID-19 pandemic, when Liu 2020 and several subsequent observational studies in Chinese hospitals reported reduced mortality in severe COVID-19 patients receiving Ta1 alongside standard care. The methodological quality varied substantially and the signal did not lead to inclusion in major Western treatment guidelines. The honest framing is that Ta1 has a substantial international evidence base, an unusually long track record of regulated clinical use, and clear efficacy signals in defined immunocompromised populations. The applicability of those signals to immune-support use in healthy adults is the standard extrapolation that has not been controlled. ## Dosage and administration The standard Zadaxin label dosing in approved indications is 1.6 mg subcutaneously twice weekly, typically administered Monday and Thursday or similar non-consecutive days. Treatment durations vary by indication: 6 months for hepatitis B, 12 months for hepatitis C combination therapy, individualized for oncology adjunct use. US compounded protocols for off-label immune support typically use 1.5 to 1.6 mg twice weekly subcutaneously, mirroring the international label. A typical 1.6 mg vial reconstituted with 1 mL bacteriostatic water gives 1.6 mg/mL. A 1.6 mg dose draws 100 units on a U100 insulin syringe (standard insulin syringes have a 100 unit / 1 mL maximum capacity). Cycling structure for off-label use is heterogeneous. Acute illness or immune-stress periods (post-surgery, severe viral infection, cancer adjunct) typically run 4 to 12 week courses. Chronic immune support is sometimes dosed continuously over months. The original Zadaxin protocol is itself a defined-duration course rather than continuous, so continuous dosing has less direct historical precedent. ## Side effects and safety Ta1 has the cleanest reported tolerability profile of any peptide on this site. Adverse events across the substantial regulated trial database are predominantly mild: occasional injection-site irritation, transient mild fatigue, and rare headache. Serious adverse events specifically attributable to Ta1 are rare in the published literature, even at the regulated population scale. Contraindications are relatively narrow given the safety profile. Pregnancy and lactation are recommended-against on absence-of-data grounds. Active organ transplantation rejection therapy or systemic immunosuppression for autoimmune disease is a relative contraindication on mechanistic grounds: stimulating T-cell function in a patient on immunosuppressive therapy could theoretically destabilize the suppression. Severe autoimmune disease is similarly a cautious area. Drug interactions are not extensively characterized but include theoretical interaction with immunosuppressives (calcineurin inhibitors, antimetabolites) and with interferon (additive immune effect, used clinically in combination protocols). ## Practical notes Lyophilized Ta1 is stable refrigerated. Once reconstituted with bacteriostatic water, refrigerate and use within 30 days. Compounded supply varies in quality; SciClone-manufactured Zadaxin is the international gold standard. Measurable subjective effects in immune-support use are inconsistent across user reports. Some users report fewer colds, faster recovery from acute illness, and reduced post-viral fatigue over a 6 to 12 week course. Others report nothing distinguishable from baseline. Objective endpoints (CD4/CD8 ratio, NK cell activity, vaccine antibody titers) are measurable but not commonly tracked in non-clinical contexts. The practical comparison vs other immune-modulating peptides: Ta1 has by far the strongest regulated clinical foundation, a long international track record, and the cleanest safety profile. The trade-offs are higher cost, complex sourcing in the US compounding pathway, and the efficacy questions in healthy adults that the regulated indications do not directly answer.